Clopidogrel, prasugrel, and ticagrelor are antiplatelet drugs that act by inhibiting the platelet P2Y 12 receptor. Any one of them is usually combined with low-dose aspirin as dual antiplatelet therapy in patients who have acute coronary syndromes or who are undergoing coronary stent implantation to decrease the risk of subsequent platelet-mediated thrombotic cardiovascular events. Many investigations have been performed to determine whether these clinical indications should be broadened. The PARTHENON clinical development program 1 for ticagrelor included five randomized, controlled, double-blind trials across the spectrum of cardiovascular diseases (Table 1). In patients who were admitted to the hospital for myocardial infarction or . . .